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WINNING ABSTRACT: Some literature suggests that outcomes of CAP in patients with solid tumor without neutropenia may be
better than in cancer patients with neutropenia. In order to investigate the role of neutrophils in this population, we
retrospectively analyzed consecutive patients with CAP admitted to 3 tertiary care hospitals from 01/2001 through 12/2005. HIV
patients were excluded. A total of 993 patients were classified as follows: Group 1: no active cancer; Group 2: solid cancer
without neutropenia; Group 3: solid cancer without neutropenia or hematologic malignancy. Age, Pneumonia Severity Index
(PSI), overall mortality, time to reach clinical stability (TCS) and length of stay in hospital (LOS) are summarized in the table. No
significant differences were found for any of the outcomes between group 2 and 3. Our results suggest that physicians should
aggressively manage cancer patients with CAP, regardless of the neutrophil count.
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MY JOB AND THE UNIT IN WHICH I WORK
I work as a visiting research fellow at the Division of Infectious
Diseases, University of Louisville (Louisville, KY, USA). Under
the leadership of Dr J. Ramirez, the Community-Acquired
Pneumonia Organization (CAPO) project was developed and
is carried out at this institution. My winning abstract is on a
study I performed on the CAPO database.
CAPO is an open organisation, with participation from well-
established international investigators as well as new investi-
gators with the common goal of fostering international
research in the field of community-acquired pneumonia
(CAP) [1]. The core study has a retrospective, observational
design and a system of internet-based clinical research. Data
from randomly selected hospitalised adult patients with a
diagnosis of CAP are collected by different institutions around
the world using a paper data collection form. Data are then
entered into a worldwide web-based data collection system
and transferred electronically to the CAPO coordinating centre
at the University of Louisville. At the coordinating centre, after
discrepancies and inconsistencies in the data are resolved and
clarified with the international investigators, cases are sub-
mitted to the database. The Division of Infectious Diseases
coordinates research, performs secondary data analysis,
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TABLE 1 Retrospective analysis of patients from three
tertiary care hospitals
Group 1
n5896
Group 2
n565
Group 3
n532
Age yrs 64¡16 67¡12 65¡17
PSI scores 82¡42 127¡29 122¡26
TCS days 3.9¡2.6 4.2¡2.6 4.7¡2.7
LOS days 7.4¡7.8 7.7¡8.6 9.0¡8.1
Mortality 44 (4.9)# 10 (15)# 3 (9.4)
Data are presented as mean¡SD or n (%). PSI: Pneumonia Severity Index; TCS:
time to reach clinical stability; LOS: length of stay in hospital. #: p50.002
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coordinates ancillary studies, and supports the preparation of
abstracts for presentation and manuscripts for publication. A
description of the study protocol, study manual and data
collection form is available from the CAPO website [2].
The core clinical study is entitled ‘‘An international observa-
tional study to evaluate the current management of hospital-
ized patients with community-acquired pneumonia’’. The
primary objective of the core study is to evaluate the quality
of care delivered to hospitalised patients with CAP. Unlike
CAP clinical trials, participants in the CAPO observational
cohort study include patients with more complex medical
problems. The CAPO cohort, therefore, more closely reflects
the real-world experience of hospitalised patients with CAP.
There are currently .3,500 cases of hospitalised patients with
CAP enrolled in the CAPO core study, representing 46
institutions from 16 countries.
MY WINNING POSTER AS PART OF MY RESEARCH
I am a clinical pulmonary fellow at the Institute of Respiratory
Diseases at the University of Milan (Milan, Italy), working
under the instruction of Prof. Blasi in the field of respiratory
infections. Our institute became part of the CAPO project in
2001. Before arriving in Louisville, I worked in a respiratory
intensive care unit treating severe pneumonia cases compli-
cated by acute respiratory failure. Among the most difficult to
treat and those most likely to have poor outcomes were
immunocompromised cancer patients, particularly those with
haematological malignancy. In fact, in patients whose immuno-
suppression is due to cancer, pneumonia accounts for a
mortality rate that is higher in comparison to patients with
pneumonia and other immunocompromised states [3, 4].
I arrived in Louisville in October 2006 to work on the CAPO
project and began investigating the outcomes of cancer
patients with CAP using the CAPO database. The strength of
the CAPO database arises from the enormous number of
patients enrolled and the presence of different clinical
outcomes, including not only the in-hospital and CAP-
related mortality, but also the hospital length of stay and the
time to clinical stability. Using these data, I was able to
conduct analyses of CAP in cancer and neutropenic patients,
focusing not only on microorganisms but also on clinical
outcomes. My study received international support as
investigators were willing to collect additional data for
patients previously enrolled in the project in order to
strengthen certain variables for analysis in the CAPO
database. I performed an ‘‘ancillary study,’’ which is a type
of study based on the modification of the core cohort-study
protocol in which new data are collected. Thanks to the well-
established web-based system and the strong relationships
that exist between CAPO investigators, I was able to perform
and conclude this study.
MY RESEARCH AS PART OF MY WORKING GROUP/
RESEARCH TEAM
The research conducted at the Division of Infectious Diseases
primarily focuses on the area of pneumonia. In addition to
CAPO, Dr Ramirez launched a nosocomial pneumonia study
in order to assess outcomes and improve processes of care.
In recent months, concentration on methicillin-resistant
Staphylococcus aureus (MRSA) pneumonia has increased in this
study, which is strengthened by the retention of the respiratory
isolates by the Infectious Diseases Laboratory (Louisville) for
genetic analysis. The division also participates in a clinical trial
evaluating the efficacy of two Food and Drug Agency
approved antibiotics in the treatment of MRSA pneumonia.
Besides pneumonia, another new area of interest for this
division is in soft tissue infections and osteomyelitis, for which
efforts to create a similar database infrastructure are in
progress.
Under the direction of Dr Ramirez, the Division of Infectious
Disease has created a unique fellowship training programme
with a strong combination of patient care and clinical
research. All observational and intervention studies are
managed by the Director of Clinical Research, Paula Peyrani,
MD. The project managers involved in areas such as
regulatory compliance and training, logistical management
and data validation Ginny Sciortino, CCRC, and Mary
Elizabeth Allen, MBA, who is a doctoral student at the
School of Public Health (Louisville). Two clinical research
fellows, Asad Amir, MD, and Mehdi Mirsaeidi, MD, MPH, are
currently working with me on CAPO and other projects. Also
involved in research are three clinical fellows and three
faculty members, Raul Nakamatsu, MD, Forest Arnold, DO,
and Marty Allen, MD. This multidisciplinary team also
includes an associate professor with the Kornhauser Health
Sciences Library (Louisville), Elizabeth Smigielski, and three
part-time statisticians from the School of Public Health who
provide statistical support for the CAPO core study, as well as
for all other research projects.
THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH
PRACTICE
In analysing the impact of cancer on outcomes of hospitalised
patients with community-acquired pneumonia, we surpris-
ingly found that patients without neutropenia had outcomes
similar to those with neutropenia. Our findings are consistent
with recent literature that has questioned the role of
neutropenia in outcomes of patients with both haematological
and solid tumours with different infections [5–7]. A possible
explanation could be found in the simultaneous impairment of
multiple aspects of the host defence system, beside neutro-
penia, that affects cancer patients hospitalised for community-
acquired pneumonia. Our results can impact strongly on
clinical practice, suggesting that physicians should manage
cancer patients with community-acquired pneumonia aggres-
sively, regardless of the type of cancer or the neutrophil count
on admission. Particularly, the lack of neutropenia during the
initial evaluation of a cancer patient with community-acquired
pneumonia should not be considered an indicator of better
clinical outcome.
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